Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • ENT
  • ENT Perspective
  • Allergic Rhinitis:...

Allergic Rhinitis: Latest Practice Insights and Treatment Approach

Written By : Dr. Kamal Kant Kohli Published On 2023-11-03T11:13:22+05:30  |  Updated On 3 Nov 2023 4:20 PM IST
Allergic Rhinitis: Latest Practice Insights and Treatment Approach
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Understanding Allergic Rhinitis(AR)

Rhinitis is generally defined as inflammation of the nasal mucosa. Allergic rhinitis (AR) is a disease that affects 400 million people worldwide. AR is often associated with co-morbid diseases such as asthma, leading to reduced quality of life and significant health economic impact. (1)

Indian Burden of AR: AR imposes a significant burden, accounting for approximately 55% of all allergies. The reported incidence of AR in India ranges between 20% and 30%. (2) As per the Global Asthma Network Survey in India, the prevalence of AR in 6-7-year-olds (children) is 7.7%, while in 13-14-year-olds (adolescents), it is 23.5%. Among adolescent school children in India, reportedly 25% experience AR, and 8.5% suffer allergic rhinoconjunctivitis. (3)

Pathophysiology of AR: Practical Overview: AR involves infiltrating inflammatory cells, including mast cells, T cells, B cells, macrophages, and eosinophils, into the nasal lining in response to allergen exposure. Activating T helper 2 (Th2) cells leads to the production of IgE by plasma cells, triggering the release of histamine, leukotrienes, and other mediators that cause symptoms such as itching, rhinorrhea, and nasal congestion. A late-phase inflammatory response further maintains symptoms by releasing additional mediators and cytokines. (2) Seasonal change and air pollution often trigger this pathway. (4)

Risk Factors for AR: The prevalence of AR has indicated an upward trend over the years, attributed to various factors. Global urbanization has led to increased levels of pollutants, including traffic-related pollutants and particulate matter. Urban areas have been reported to have a higher incidence of AR than rural areas. Climate changes have also contributed to a prolonged pollen season, resulting in more frequent seasonal allergies. Smoking and tobacco consumption have been associated with an increased risk of AR. (1)

Diagnosis of AR: Patient Assessment, Physical Examination & Allergy Testing

During patient history-taking, individuals with AR commonly report several hallmark symptoms. These include nasal congestion, nasal itching, rhinorrhea (runny nose), and sneezing. Allergic conjunctivitis, which refers to inflammation of the membrane covering the white part of the eye, is often associated with AR. Typical symptoms of allergic conjunctivitis include redness, excessive tearing, and itching of the eyes. (2)

The physical examination of individuals with suspected AR involves assessing various areas. Signs such as persistent mouth breathing, nose rubbing, nasal crease, frequent sniffling or throat clearing, and allergic shiners (dark circles under the eyes) may indicate AR. Nasal examination reveals swollen nasal mucosa and pale secretions. Nasal examination reveals swollen nasal mucosa and pale secretions. The internal endoscopic examination helps identify structural abnormalities like septal deviation, nasal ulcerations, and nasal polyps. Ears are evaluated for Eustachian tube dysfunction and fluid behind the eardrum. Sinus examination includes palpation for tenderness and sensitivity testing of the maxillary teeth. The posterior oropharynx is examined for signs of postnasal drip, while the chest and skin are checked for concurrent asthma or dermatitis. Skin prick testing is the primary method used to identify specific allergic triggers. Allergen-specific IgE tests can be performed, measuring specific IgE levels against allergens (2)

Managing AR: From Allergen Avoidance to Immunotherapy- A Comprehensive Approach

Avoid Exposure to Allergens: The initial approach to treating AR is to avoid exposure to relevant allergens and irritants. This includes minimizing contact with common triggers such as house dust mites, moulds, pets, and pollens. Additionally, it is important to advise patients to avoid tobacco smoke, as it can exacerbate symptoms of AR. (2)

Pharmacological Therapy: The first-line pharmacological treatment for AR consists of second-generation oral antihistamines, such as fexofenadine, cetirizine, desloratadine, and loratadine. These medications have effectively reduced sneezing, itching, and rhinorrhea symptoms. Second-generation oral antihistamines are widely used to relieve and improve the overall quality of life among individuals with AR. They have a better safety and tolerance profile for long-term use with a lower risk of sedation or impaired cognitive function. (2)

Immunotherapy: Allergen immunotherapy is a therapeutic approach that involves gradually administering increasing amounts of relevant allergens to a patient through subcutaneous injections. This treatment is particularly effective for patients with intermittent AR caused by seasonal allergens. Allergen immunotherapy is typically administered year-round, starting with weekly incremental doses over 6-8 months. This is followed by maintenance injections of the maximum tolerated dose given every 3-4 weeks for 3-5 years. (2)

Other common pharmacological agents, such as intranasal corticosteroids(INS), and Leukotriene Receptor Antagonists (LTRA), such as montelukast and zafirlukast, are used to treat AR. (2)

Importance of Combination Therapy- Effective Tackling of AR Symptoms: A combination of drugs such as intranasal corticosteroids, antihistamine nasal spray, antihistamines, and leukotriene receptor antagonists are frequently used. (2) Histamines play a role in the pathophysiology of AR and are responsible for several symptoms, including rhinorrhea, nasal itching, and sneezing. Leukotrienes, on the other hand, primarily result in increases in vascular permeability and nasal airway resistance. Therefore, blocking these two mediators with antihistamines and LTRAs may offer more advantages than inhibiting one mediator. Optimal medical management and outcomes in AR could be achieved by combining an LTRA and an antihistamine, which may increase patient compliance. (5)

Montelukast And Fexofenadine For AR: Clinical Review & Therapeutic Perspectives

Fexofenadine, a second-generation antihistamine, is an active metabolite of terfenadine. It is approved by the US FDA (United States Food and Drug Administration) for treating seasonal AR in children (6 months and older) and adults. The mechanism of action involves selective antagonism of H1 receptors on various cell surfaces in different organ systems. Additionally, fexofenadine can inhibit the release of inflammatory mediators from mast cells, basophils, and other inflammatory cells. After oral administration, fexofenadine is rapidly absorbed, reaching peak plasma concentrations within one hour. It has a plasma protein binding capacity of up to 70%. (6) The leukotriene receptor antagonist Montelukast binds to the cysteinyl leukotriene receptor for leukotrienes D4 and E4 with a high affinity. Following oral treatment, montelukast is immediately absorbed. Montelukast is the most widely used anti-leukotriene and the only one authorized for use in pediatric patients (7)

Fexofenadine and Montelukast Combinations Help Relieving Symptoms of AR: A prospective, randomized, double-blind, parallel, active-controlled study conducted by Mohini Sachin Mahatme et al. compared the efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine combination in patients of AR. The study enrolled 70 AR patients (moderate-severe intermittent or mild chronic, aged 18-65 years) The evaluation of total nasal symptom score (TNSS), i.e. intensity of nasal symptoms ( rhinorrhea, nasal itching, nasal obstruction, and sneezing) from baseline to the fourth week demonstrated a significant difference (p<0.05) in both groups. The mean change of TNSS was statistically significant (p< 0.0033) in the montelukast-fexofenadine group compared to montelukast-levocetirizine. The study concluded that montelukast-fexofenadine is effective in AR patients with moderate to severe or mild chronic symptoms. (8)
Fexofenadine and Montelukast Combination Efficacious in Indian AR Patients: An observational study evaluated the efficacy and safety of montelukast and fexofenadine fixed-dose combination in treating allergic rhinitis(AR). The study enrolled 809 AR patients w and treated with montelukast 10 mg plus fexofenadine 120 mg fixed-dose combination once daily for 14 days. The fixed-dose combination of fexofenadine plus montelukast significantly reduced the total symptom score (sum of total nasal symptom score and total ocular symptom score), total nasal symptom score (nasal congestion, rhinorrhea, nasal itching, and sneezing) and total ocular symptom score (itching/burning eyes, tearing/ watering eyes, and eye redness) (p<0.0001 for all parameters). The fixed-dose combination of fexofenadine plus montelukast was efficacious and tolerated in AR in Indian adult patients. (9)

Montelukast And Fexofenadine Combination Safe and Effective in Indian Pediatric AR Patients: Abha Kumari conducted a study to compare the efficacy and safety of Levocetirizine plus montelukast and fexofenadine plus montelukast on school-going children (aged 8-15 years) The study enrolled 80 AR patients and divided them into two treatment arms (Levocetirizine plus Montelukast group and Fexofenidine plus Montelukast group). The total nasal symptoms (running nose, sneezing, nasal congestion, nasal irritation) and ocular symptoms (watery eye) scores were significantly reduced in the fexofenadine plus montelukast group (p<0.001). The study inferred that the combination of fexofenadine and montelukast effectively treated allergic rhinitis in children. (10)

Key Points
  • Allergic Rhinitis(AR) is a common allergic condition that impacts the quality of life of an individual. In India, AR affects approximately 20-30% of the population.
  • The management of AR is allergen avoidance, antihistamines and immunotherapy, nasal steroids, leukotriene receptor antagonists, and their combination with antihistamine agents.
  • A combination of fexofenadine and montelukast could boost the therapeutic efficacy of AR treatment.
  • Clinical studies have demonstrated the efficacy of fexofenadine plus montelukast in relieving symptoms of AR.
Fexofenadine plus Montelukast Combination has demonstrated efficacy in treating AR, relieving symptoms such as nasal congestion, sneezing, itching, and runny nose. Its effectiveness, safety profile, and availability in various formulations make it a valuable consideration for managing AR. (8,9,10)
References:

1. Nur Husna, S. M., Tan, H.-T. T., Md Shukri, N., Mohd Ashari, N. S., & Wong, K. K. (2022). Allergic rhinitis: A clinical and pathophysiological overview. Frontiers in Medicine, 9, 874114.

2. Small, P., Keith, P. K., & Kim, H. (2018). Allergic rhinitis. Allergy, Asthma, and Clinical Immunology: Official Journal of the Canadian Society of Allergy and Clinical Immunology, 14(Suppl 2), 51.

3. Barne, M., Singh, S., Mangal, D. K., Singh, M., Awasthi, S., Mahesh, P. A., Kabra, S. K., Mohammed, S., Sukumaran, T. U., Ghoshal, A. G., Sinha, S., Kochar, S. K., Singh, N., Singh, U., Patel, K. K., Sharma, A. K., Girase, B., Madas, S., Chauhan, A., … Salvi, S. (2022). Global Asthma Network Phase I, India: Results for allergic rhinitis and eczema in 127,309 children and adults. The Journal of Allergy and Clinical Immunology. Global, 1(2), 51–60.

4. Naclerio R, Ansotegui IJ, Bousquet J, Canonica GW, D'Amato G, Rosario N, Pawankar R, Peden D, Bergmann KC, Bielory L, Caraballo L, Cecchi L, Cepeda SAM, Chong Neto HJ, Galán C, Gonzalez Diaz SN, Idriss S, Popov T, Ramon GD, Ridolo E, Rottem M, Songnuan W, Rouadi P. International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants: Impact of air pollution on patients with AR: Current knowledge and future strategies. World Allergy Organ J. 2020 Apr 3;13(3):100106. doi: 10.1016/j.waojou.2020.100106.

5. Walekar, A., Chodankar, D., Naqvi, M., & Trivedi, C. (n.d.). Assessment of bioequivalence of fexofenadine and montelukast fixed-dose combination tablet versus separate formulations of the individual components at the same dose levels. Ijpsonline.com. Retrieved July 15, 2023, from https://www.ijpsonline.com/articles/bioequivalence-of-fexofenadine-and-montelukast-fixed-dose-combination-tablet-with-individual-components-singledose-rando.pdf

6. Craun, K. L., & Schury, M. P. (2022). Fexofenadine. StatPearls Publishing.

7. Baççıoğlu, A. (2013). Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis and asthma comorbidity. Journal of Medical Updates, 3(1), 34–39.

8. Mahatme, M. S., Dakhale, G. N., Tadke, K., Hiware, S. K., Dudhgaonkar, S. D., & Wankhede, S. (2016). Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Indian Journal of Pharmacology, 48(6), 649–653.

9. Naik, M., Nayak, A., Khandeparkar, P., & Mukaddam, Q. (2013). Efficacy and safety of montelukast plus fexofenadine fixed-dose combination in allergic rhinitis : Results of a post-marketing study in India.

10. Abha Kumari, Sandeep Kumar. A Study of Levocetirizine and Monteleukast versus Fexofenidine and Monteleukast in School Going Children with Allergic Rhinitis. Int J Med Res Prof. 2018 Jan; 4(1):268-71. DOI:10.21276/ijmrp.2018.4.1.054

allergic rhinitisARallergic rhinitis managementallergic rhinitis diagnosisallergic rhinitis therapyfexofenadineantihistaminemontelukastltrafexofenadine and montelukast combinationallegra mallegra m in ar
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Featured image representing medico legal

What's the Role of Expert Opinion in Medical Negligence?

7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

Darbapoetin Alfa In Chemotherapy Induced Anaemia: Check out 5 takeaways from recent study

Darbapoetin Alfa In Chemotherapy Induced Anaemia: Check out 5 takeaways from recent study

Biosimilar Denosumab of Alkem (Denuril) shows Comparable Efficacy in Treating Postmenopausal Osteoporosis in Indian Women

Biosimilar Denosumab of Alkem (Denuril) shows Comparable Efficacy in Treating Postmenopausal...

View All

Journal Club Today

Medical Journalism: Need of the Hour - Ft: Dr Prem Aggarwal (Chairman, Medical Dialogues), Dr Nandita Mohan (Head, MDTV Division, Medical Dialogues)

Medical Journalism: Need of the Hour - Ft: Dr Prem Aggarwal (Chairman, Medical Dialogues), Dr...

View All

Health News Today

Health Bulletin 08/ May/ 2025

Health Bulletin 08/ May/ 2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok